HIV Prevention With PrEP Among People on Opioid Replacement Therapy (NCT07160075)
Improving Access to HIV Pre-exposure Prophylaxis: Implementation and Evaluation of Innovative HIV Prevention Services Among Persons on Opioid Replacement Therapy in Western Canada: Prospective, Implementation Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.
Who can join: Review the eligibility criteria below.
Location: Sheldon M Chumir Health Centre — Calgary, Alberta
Age range: 16 Years
🧪 Interventions in This Study
- Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Sheldon M Chumir Health Centre — Calgary, Alberta
- Queen City Wellness Pharmacy — Regina, Saskatchewan
- Mayfair Drugs Pharmacy — Saskatoon, Saskatchewan
- Pharmasave Riversdale Pharmacy — Saskatoon, Saskatchewan
- The Medicine Shoppe Pharmacy — Saskatoon, Saskatchewan
- Meadowgreen Pharmacy — Saskatoon, Saskatchewan
📞 Contact the Study Coordinator
Phone: (403) 210-6093
Email: cbshukal@ucalgary.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV - Human Immunodeficiency Virus
- Improving the HIV Care Continuum With mHealth Technology — Columbia, South Carolina
- Coronary Artery Calcium Score in HIV Mexican Population (The CACsHIVMex Study) — León, Guanajuato
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity — Mexico City,
Explore by condition: All HIV - Human Immunodeficiency Virus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.